A detailed history of Sheaff Brock Investment Advisors, LLC transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Sheaff Brock Investment Advisors, LLC holds 15,250 shares of AVXL stock, worth $86,620. This represents 0.01% of its overall portfolio holdings.

Number of Shares
15,250
Previous 17,750 14.08%
Holding current value
$86,620
Previous $90,000 28.89%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 30, 2024

SELL
$3.39 - $5.02 $8,475 - $12,549
-2,500 Reduced 14.08%
15,250 $64,000
Q1 2024

May 14, 2024

SELL
$4.55 - $6.75 $88,725 - $131,625
-19,500 Reduced 52.35%
17,750 $90,000
Q4 2023

Feb 08, 2024

BUY
$5.04 - $9.95 $78,120 - $154,225
15,500 Added 71.26%
37,250 $346,000
Q3 2022

Nov 03, 2022

BUY
$8.9 - $12.86 $17,800 - $25,720
2,000 Added 10.13%
21,750 $224,000
Q2 2022

Aug 02, 2022

SELL
$7.31 - $12.84 $25,585 - $44,940
-3,500 Reduced 15.05%
19,750 $198,000
Q1 2022

May 16, 2022

BUY
$9.74 - $17.69 $7,305 - $13,267
750 Added 3.33%
23,250 $286,000
Q1 2022

May 06, 2022

SELL
$9.74 - $17.69 $132,658 - $240,937
-13,620 Reduced 37.71%
22,500 $277,000
Q4 2021

Jun 02, 2022

BUY
$16.88 - $23.31 $12,660 - $17,482
750 Added 2.12%
36,120 $626,000
Q4 2021

Feb 03, 2022

BUY
$16.88 - $23.31 $35,616 - $49,184
2,110 Added 6.34%
35,370 $613,000
Q3 2021

Nov 03, 2021

BUY
$16.82 - $25.75 $36,835 - $56,392
2,190 Added 7.05%
33,260 $597,000
Q2 2021

Aug 16, 2021

BUY
$10.16 - $28.86 $35,560 - $101,010
3,500 Added 12.69%
31,070 $710,000
Q1 2021

May 11, 2021

BUY
$5.17 - $16.13 $142,536 - $444,704
27,570 New
27,570 $412,000

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $443M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Sheaff Brock Investment Advisors, LLC Portfolio

Follow Sheaff Brock Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sheaff Brock Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sheaff Brock Investment Advisors, LLC with notifications on news.